Pharmaceutical reliability with a Georgian team
Neuropharm Georgia LLC was founded with a single clear principle: to supply the Georgian market with high-quality medicines while fully complying with regulatory requirements.
Our story, mission, and vision
How we started
Our top priority is the import and distribution of medicines manufactured in accordance with EU GMP standards, at both the finished dosage form (FDF) and active pharmaceutical ingredient (API) levels.
We collaborate with international manufacturers who meet the European Union's strict quality requirements, ensuring the safety, efficacy, and full regulatory compliance of every product.
Neuropharm Georgia's mission is to become a trusted bridge between global pharmaceutical quality and the local market, advancing access to high-quality medicines across the region.
Complete, fully integrated service from manufacturing to pharmacy shelves
We unite every stage of the supply chain into a single system to deliver quality, continuity, and operational simplicity.
For international pharmaceutical companies
If you're planning to enter the Georgian market, we offer comprehensive support: from registration and regulatory processes to logistics and distribution. We act as your local representative and trusted guide for effective market entry.
For the local market
We offer pharmacy chains, hospitals, and clinical centers a unified, stable, and efficient supply model from a single source. Our system delivers optimized processes, uninterrupted distribution, and consistent access to high-quality products.
Become our partner
Tell us your needs and we'll design a tailored, continuous, and reliable supply plan built around your business.
Contact usLicensed and certified
Our pharmaceutical activity license is issued by the Georgian Ministry of Health. Every import is carried out in full regulatory compliance.
License №438739260Where we want to be in 2030
By 2030, our goal is to become the leading independent pharmaceutical importer in Georgia: consolidating 50+ suppliers from Europe and India, building regional cold-chain infrastructure, and beginning collaboration with clinical trial sponsors.